Immunisation Update 2026

Vaccination Gaps Exposed

Australia's immunisation landscape is shifting under the weight of recent declines in coverage rates. Childhood vaccination levels, once a global benchmark, have dipped to 91-94% for key milestones as of June 2024, falling short of the 95% needed for herd immunity against diseases like measles. This trend, accelerating since the COVID-19 pandemic, stems from disrupted routines, access barriers, and growing hesitancy. The National Immunisation Strategy 2025-2030, released late last year, sets ambitious targets to reverse this by 2030, focusing on equity for groups like Aboriginal and Torres Strait Islander peoples, where rates lag further at 89-95%.

Recent policy tweaks underscore the immediacy. In September 2025, the National Immunisation Program replaced Prevenar 13 and Pneumovax 23 with Prevenar 20 for children and adolescents, broadening defense against 20 pneumococcal strains. This change, advised by the Australian Technical Advisory Group on Immunisation, aims to curb invasive pneumococcal disease, which hospitalises hundreds annually. First Nations children, facing higher infection risks, now get an extra dose, reflecting data on disparities.

Outbreaks amplify the stakes. Whooping cough notifications exceeded 23,000 in 2025, the highest since 1991, spilling from a 2024 surge. Measles cases climbed to 158 last year, mostly imported but threatening local transmission in under-vaccinated pockets. These clusters, often in regional or socio-economically challenged areas, expose vulnerabilities: a single case in a low-coverage community could spark epidemics, echoing global surges post-2022.

RSV adds another layer. After severe 2025 seasons overwhelming hospitals, Western Australia rolled out free vaccines for aged care residents aged 65 and over from mid-May 2026, targeting 15,000 people at a $2.6 million cost. Nationally, advocacy pushes for broader access, as private doses hit $300, leaving many seniors exposed to hospitalisation risks. This follows infant and maternal programs, but gaps persist for other adults.

Non-obvious tensions lurk beneath. Post-COVID lessons reveal equity pitfalls: rapid rollouts favored urban areas, eroding trust in remote or culturally diverse communities. Misinformation, spilling from U.S. debates, fuels parental distress—32% in a 2025 survey cited anxiety as a barrier. Trade-offs include balancing new tech like mRNA vaccines with onshore manufacturing needs, amid climate-driven zoonotic threats. A proposed no-fault compensation scheme could boost confidence, but implementation hurdles remain.

Stakes are tangible: low rates mean higher hospital burdens, with preventable diseases costing billions in care. Deadlines loom, like annual strategy reviews and 2026 data upgrades. Inaction risks undoing eliminations—measles since 2014, rubella since 2018—potentially reversing life expectancy gains, especially in priority groups.